Sydnexis Receives Positive CHMP Opinion for SYD-101 in Europe to Slow Pediatric Myopia Progression Sydnexis, Inc. a pre-commercial stage biopharmaceutical company specializing in ophthalmic therapeutics, has announced a significant regulatory…
$23.3Bn Antibody-Drug Conjugate Market Trends & Forecasts, 2035: 530+ Therapies, 140+ Developers The antibody-drug conjugate (ADC) market is poised for significant growth, with projections indicating an increase from USD 7.72…
Align Technology Launches Invisalign® With Mandibular Advancement for Class II Correction Align Technology, Inc. (Nasdaq: ALGN), a globally recognized medical device company specializing in digital orthodontics and restorative dentistry, has…
MANSCAPED Unveils TCS Ball Hero Bundle for Testicular Cancer Awareness MANSCAPED, the global leader in men’s grooming, has built a reputation not only for its innovative grooming products and clever…
Mirion Enhances Radiopharmaceutical Production with Cutting-Edge Apex-Guard Software Mirion Technologies (NYSE: MIR), a global leader in radiation safety solutions, has announced the latest release of its Apex-Guard gamma spectroscopy software.…
Devonian Announces Delay in Financial Results Release Devonian Health Group Inc. (“Devonian” or the “Company”) (TSXV: GSD; OTCQB: DVHGF), a clinical-stage biopharmaceutical company specializing in the development of innovative therapies…
ENHERTU Phase 3 DESTINY-Gastric05 Trial Starts for Untreated HER2+ Advanced Gastric Cancer The first patient has been successfully dosed in the DESTINY-Gastric05 phase 3 trial, which aims to evaluate the…
LucyRx Unveils Bold Brand Identity, Celebrates Key Milestones to Simplify PBM and Enhance Patient Care LucyRx, a next-generation pharmacy benefit manager (PBM), is shaking up the landscape of prescription care…
Omeros Corporation Announces Fourth Quarter and Full-Year 2024 Financial Results Omeros Corporation has announced its recent developments, clinical updates, and financial results for the fourth quarter and full year ended…
Lilly’s RNA Silencer Achieves Nearly 94% Reduction in Key Cardiovascular Biomarker Eli Lilly has made a groundbreaking advancement in cardiovascular medicine with its investigational small interfering RNA (siRNA) therapeutic, lepodisiran,…
Sanofi and Alnylam Secure Landmark RNAi Approval for Hemophilia A & B Sanofi and Alnylam have achieved a significant milestone with the U.S. Food and Drug Administration (FDA) granting approval…
European Commission Approves TIVDAK® for Recurrent or Metastatic Cervical Cancer Genmab A/S has announced that the European Commission (EC) has officially granted marketing authorization for TIVDAK® (tisotumab vedotin), an antibody-drug…